BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 27,803 shares of the firm's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total transaction of $9,055,715.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
John Oyler also recently made the following trade(s):
- On Wednesday, July 9th, John Oyler sold 27,802 shares of BeOne Medicines stock. The stock was sold at an average price of $253.38, for a total value of $7,044,470.76.
- On Monday, June 23rd, John Oyler sold 3,174 shares of BeOne Medicines stock. The shares were sold at an average price of $261.61, for a total transaction of $830,350.14.
BeOne Medicines Stock Up 1.0%
ONC stock traded up $3.42 on Monday, hitting $337.82. The company had a trading volume of 112,332 shares, compared to its average volume of 340,339. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The stock's 50-day simple moving average is $310.42 and its 200 day simple moving average is $268.97. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $170.99 and a 12-month high of $351.27.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.48 by $0.36. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. On average, research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA purchased a new position in BeOne Medicines in the 2nd quarter worth about $1,231,720,000. Temasek Holdings Private Ltd purchased a new position in BeOne Medicines in the 2nd quarter worth about $244,603,000. Marshall Wace LLP purchased a new position in BeOne Medicines in the 2nd quarter worth about $113,190,000. Baird Financial Group Inc. bought a new position in BeOne Medicines during the 2nd quarter worth about $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in BeOne Medicines during the 2nd quarter worth about $73,347,000. Hedge funds and other institutional investors own 48.55% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the stock. Royal Bank Of Canada upped their target price on shares of BeOne Medicines from $349.00 to $364.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Wall Street Zen lowered shares of BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Guggenheim upped their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a research report on Thursday, August 7th. Morgan Stanley upped their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research report on Friday, June 27th. Finally, Barclays assumed coverage on shares of BeOne Medicines in a research report on Thursday. They set an "overweight" rating and a $385.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat, BeOne Medicines currently has an average rating of "Buy" and a consensus target price of $336.30.
Get Our Latest Stock Report on BeOne Medicines
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Read More
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
